Overview
Bioactive peptides and small molecules that modulate neurotransmitter systems, neurotrophic factor signaling, synaptic plasticity, and cognitive function. These compounds are investigated for their roles in neuroprotection, neuroregeneration, memory enhancement, anxiolysis, and the management of age-related cognitive decline.
Overview¶
Neurocognitive peptides represent a diverse class of compounds that act on central nervous system (CNS) targets to modulate brain function. Unlike classical small-molecule neuropharmaceuticals, neuropeptides and peptide-inspired compounds often exhibit high receptor specificity, favorable safety profiles, and the ability to stimulate endogenous neurotrophic factor production. The AMP Peptide Research Database covers four key neurocognitive compounds:
| Peptide | Class | Mechanism | Primary Research Targets |
|---|---|---|---|
| Semax | Synthetic ACTH(4–10) analogue (heptapeptide) | Neurotrophic factor induction, BDNF upregulation | Cognition enhancement, neuroprotection, neural recovery research |
| Selank | Synthetic tuftsin analogue (heptapeptide) | GABAergic modulation, enkephalinase inhibition | Anxiolysis, cognitive enhancement, immunomodulation |
| Noopept | Dipeptide (cycloprolylglycine analogue) | AMPA receptor modulation, BDNF/TrkB signaling | Nootropic, neuroprotection, memory consolidation |
| Cerebrolysin | Porcine brain-derived peptide cocktail | Multifactorial neurotrophic support | Neuroregeneration, age-related cognitive decline research |
🔬 How Neurocognitive Peptides Work¶
1. Neurotrophic Factor Induction¶
Semax and Noopept both upregulate brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) , activating TrkB receptor signaling:
- BDNF/TrkB signaling: Promotes neuronal survival, synaptic plasticity, and long-term potentiation (LTP)
- CREB phosphorylation: Downstream activation of transcription factors for neuroplasticity genes
- cAMP response element (CRE) activation: Enhances memory-related gene expression
2. Neurotransmitter Modulation¶
- Semax: Modulates dopaminergic and serotonergic systems; increases dopamine receptor density
- Selank: Enhances GABAergic tone via benzodiazepine-independent mechanism; modulates serotonin and dopamine metabolism
- Noopept: Facilitates AMPA receptor-mediated glutamatergic transmission
- Cerebrolysin: Mimics endogenous neurotrophic factors (BDNF, GDNF, CNTF, NT-3)
3. Neuroprotection & Regeneration¶
- Antioxidant activity: Reduces oxidative stress in neuronal tissue
- Anti-apoptotic pathways: Bcl-2 upregulation, caspase inhibition
- Synaptogenesis: Promotes dendritic spine formation and synapse maturation
- Neurogenesis: Stimulates neural stem/progenitor cell proliferation
📊 Key Properties at a Glance¶
| Peptide | CAS Number | MW (Da) | Sequence Length | Mechanism | Half-life |
|---|---|---|---|---|---|
| Semax | 80714-61-0 | 706.8 | 7 aa | Neurotrophic factor inducer | ~30 min (intranasal) |
| Selank | 129954-34-3 | 756.9 | 7 aa | GABAergic modulator | ~20 min (intranasal) |
| Noopept | 157115-85-0 | 342.4 | Dipeptide (non-natural) | AMPA/BDNF modulator | ~2–5 hours (oral) |
| Cerebrolysin | N/A (mixture) | Variable (120–10,000 Da) | Peptide cocktail | Multifactorial neurotrophic | ~4–6 hours |
🧪 Research Evidence Summary¶
| Compound | Key Finding | Reference |
|---|---|---|
| Semax | Improved cognitive function in post-stroke subjects; reduced infarct volume in ischemia models | DOI: 10.1007/s10517-006-0185-2 |
| Selank | Anxiolytic effects comparable to benzodiazepines without sedation; enhanced cognitive performance | DOI: 10.1007/s10517-008-0083-x |
| Noopept | Enhanced learning and memory in rodent models; neuroprotective in excitotoxicity models | DOI: 10.1007/s11064-007-9337-2 |
| Cerebrolysin | Improved functional outcomes in age-related cognitive decline research; promoted neurogenesis in CNS injury models | DOI: 10.3233/JAD-143045 |
⚗️ Formulation and Reconstitution¶
| Factor | Semax | Selank | Noopept | Cerebrolysin | |--------|-------|-------|---------|-------|-------------| | Solvent | Bacteriostatic water | Bacteriostatic water | Water or saline | Already in solution | | Form | Lyophilized powder | Lyophilized powder | Crystalline powder | Sterile solution (ampule) | | Storage (Lyophilized) | −20°C | −20°C | 2–8°C | 15–25°C (prepared) | | Storage (Reconstituted) | 2–8°C (7 days) | 2–8°C (7 days) | 2–8°C (14 days) | Per manufacturer | | Typical Route | Intranasal (drops/spray) | Intranasal | Oral/sublingual | Intravenous/IM |
🧪 Research Dosing Overview¶
| Peptide | Typical Research Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Semax | 200–600 μg | Intranasal | 1–2× daily | 1–3 months |
| Selank | 200–600 μg | Intranasal | 1–2× daily | 1–3 months |
| Noopept | 10–20 mg | Oral | 2–3× daily | 1–3 months |
| Cerebrolysin | 5–20 mL | IV slow infusion | 3–5× weekly | 4–12 weeks |
📚 Selected References¶
- Myasoedov NF, et al. (1999). Semax — synthetic ACTH(4–10) analogue with neurotrophic effects. Bulletin of Experimental Biology and Medicine. DOI: 10.1007/s10517-006-0185-2
- Kozlovsky N, et al. (2008). Selank — anxiolytic and cognitive effects. Bulletin of Experimental Biology and Medicine. DOI: 10.1007/s10517-008-0083-x
- Ostrovskaya RU, et al. (2007). Noopept — neuroprotective and nootropic effects. Neurochemical Research. DOI: 10.1007/s11064-007-9337-2
- Alvarez XA, et al. (2015). Cerebrolysin in Alzheimer's disease. Journal of Alzheimer's Disease. DOI: 10.3233/JAD-143045
- Seif-El-Nasr M, et al. (2009). Cerebrolysin attenuates cerebral ischemia. Brain Research Bulletin. DOI: 10.1016/j.brainresbull.2009.07.007